Sign in
Not yet recruitingNo phase

Gapless ECG-Monitoring for Stroke Prevention by Atrial Fibrillation Detection (GEMS-PAF-randomized Trial) - A Multi-centre, Randomized Controlled Outcome Trial.

Key facts

Who runs it
Medical University of Vienna
Where
Austria1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
442 people, planned
Starts
20 Nov 2026
Expected to end
20 Nov 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ultra-early Implantable loop recorder (ILR) implantation
  • Conventional stroke unit care ECG-monitoring
Record updated
17 November 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Any stroke/TIA without previously detected AF - if TIA: corresponding lesion on brain MRI/CT OR if no corresponding lesion on brain imaging: Speech disturbance or paresis at the index event AND duration of symptoms >10 minutes required
  • Age ≥ 50 and; for patients age 50-59 years at least one of the following risk factors: prior stroke/TIA to index stroke (includes covert/silent strokes on neuroimaging), diabetes, hypertension, current smoking, or heart failure
  • Index event (Stroke/TIA) within 72h
  • CHA2DS2-Vasc score >3
  • Written informed consent by the patient

Who cannot take part

  • Any history of AF/atypical flutter or any documented AF/atypical flutter prior to inclusion
  • Life expectancy <1 year for reasons other than stroke
  • Age below 50 years
  • Indication for oral anticoagulation at inclusion
  • Absolute contraindication for oral anticoagulation at inclusion
  • Implanted pacemaker device or cardioverter/defibrillator
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

1. What is the purpose of this clinical trial?

Read full original descriptionShow less

All of the participants in this trial have been diagnosed with a stroke or transitoric ischaemic attack within 72 hours of inclusion. Strokes are usually caused by a blood clot, which subsequently leads to a blockage of a blood vessel in the brain. In more than 20% of patients who have had a stroke or a transient ischemic attack (TIA, a temporary reduction in blood flow to the brain), atrial fibrillation (AF) is detectable on the electrocardiogram (ECG) as a possible cause. AF is a cardiac arrhythmia characterized by irregular activity in the atria, affecting a total of 1-2% of the population. This means that approximately 100,000 people in Austria are affected. AF is also an age-related cardiac arrhythmia, so that its prevalence is already 6% among people over 65 and up to 20% among those over 80. The risk of a recurrent stroke is five times higher in patients with AF; however, this risk can be significantly reduced through the use of blood-thinning medications. However, many patients suffer from "silent" atrial fibrillation-which they themselves do not notice-that may go undetected using standard monitoring methods in the hospital or, later, on an outpatient basis. Standard monitoring methods consist of a resting electrocardiogram (ECG) upon admission to the hospital, the ECG recorded during the first few days of hospitalization in the stroke unit, and usually also a long-term ECG (Holter ECG monitoring, typically over 24 hours) performed as part of further inpatient treatment; the latter can be repeated on an outpatient basis after discharge. These measures can improve the detection rate of AF. One problem, however, is that time gaps arise between the individual monitoring steps, which means that a AF episode may go unnoticed. Since 2016, international treatment guidelines have also recommended extended, continuous ECG monitoring. One option available for this purpose is the implantable loop recorder (ILR), which is implanted under the skin and continuously records an ECG (loop = without interruption) for 3-5 years. The goal of this study is to investigate whether the early implantation of a loop recorder-already in the stroke unit-can detect atrial fibrillation to a greater extent than conventional, routine standard monitoring, and thereby prevent the occurrence of a recurrent stroke within one year. For this, it is necessary that 1) two groups be formed through random assignment and 2) a control magnetic resonance imaging (MRI) scan of the skull be performed after 12 months to detect even "silent" strokes. 2. How does the clinical trial work, what is an implantable loop recorder, and how is it implanted?

The trial is being conducted at several hospitals in Austria. The departments leading the trial at the AKH are the Departments of Cardiology and Neurology. The aim of the study is to determine whether continuous ECG monitoring, initiated early-shortly after the stroke-can detect sudden-onset atrial fibrillation more frequently or earlier than a routine monitoring regimen used in everyday clinical practice. Half of all patients enrolled in the study will have a loop recorder implanted while they are still in the stroke unit, within the first 5 days after the stroke. The loop recorder is an established standard of care. This decision is made randomly (2 groups). The loop recorder is usually implanted on the left side of the chest during a minor surgical procedure. At this site, the doctor makes a small incision (approximately 1 cm long) under local anesthesia, through which the loop recorder is inserted directly under the skin. The incision is closed with sterile adhesive strips (rarely with a suture). A commercially available loop recorder from Abbott®, which has been used for this indication for several years, will be used-specifically, the "Assert-IQ" model. The loop recorder transmits events recorded daily to a network via the cellular network. Within this network, the physician can access patient data and take action as needed. The procedure typically takes only a few minutes and is minimally invasive. The loop recorder is used only for recording and documenting, not for treating cardiac arrhythmias. Once the wound has healed, malfunctions of the device are rare. However, external factors (e.g., electrical devices) can cause the loop recorder to malfunction.

More frequent detection of atrial fibrillation is expected as a result of more intensive ECG monitoring using an implantable loop recorder (ILR). In patients with AF following a stroke, oral anticoagulation with Marcumar or a related medication is associated with a significant reduction in the risk of recurrent strokes. We anticipate that, as a result, a larger proportion of patients will be treated with oral anticoagulants, which will in turn reduce the risk of recurrent strokes.

The 2 groups in the trial

  • Group 1 - Gapless ECG-monitoringTreatment being tested

    Gapless ECG-monitoring - implantation of an implantable loop recorder directly after ECG-monitoring during stroke unit admission.

    Treatment: Ultra-early Implantable loop recorder (ILR) implantation

  • Group 2: Conventional stroke unit care by standard ECG-monitoringExisting treatment, for comparison

    Conventional stroke unit care by standard ECG-monitoring throughout the first days after the index event (Stroke/TIA) and use of 24-72h-Holter ECG examination during hospital admission and/or after discharge in the ambulatory setting according to the post-stroke follow-up protocols of the treating stroke center.

    Treatment: Conventional stroke unit care ECG-monitoring

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
17 November 2026